KKL 顾客使用本产品发表的 0 篇科研文献

Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death.

Milatuzumaba（5 μg/mL；8-48 小时）增强 MCL 细胞系和原发性患者肿瘤细胞的细胞死亡。
Milatuzumaba（5 μg/mL；0.5-2 h）在 Jeko、Mino 和 SP-53 细胞中介导细胞毒性，部分取决于 ROS 的产生和线粒体跨膜电位的丧失。
Milatuzumaba（5 μg/mL；4 小时）抑制 NF-κB 通路并诱导细胞凋亡，凋亡机制与 caspase 裂解、Bcl-2 家族成员失调或诱导自噬无关。

These data are for reference only.

Milatuzumaba（15 mg/kg/天；腹腔注射；每 3 天一次）显着提高携带 Jeko 癌细胞的雌性 SCID 小鼠的存活率。并且Milatuzumaba与Rituximab (HY-P9913) 在该小鼠模型中具有协同作用。

These data are for reference only.

Shipping with dry ice.

Store at -20˚C